PMC:7546122 / 3706-4111 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T16","span":{"begin":323,"end":329},"obj":"Body_part"}],"attributes":[{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"The current study tested a representative number of IVIG lots for nAbs against SARS-CoV-2 and the longer-circulating HCoV-229E, to establish clarity about cross-neutralization of the pandemic virus by antibodies induced by earlier circulating seasonal coronaviruses. In addition, results from the ongoing monitoring of the plasma donor community for the development of SARS-COV-2 antibodies are presented."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T21","span":{"begin":79,"end":87},"obj":"Disease"},{"id":"T22","span":{"begin":369,"end":373},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The current study tested a representative number of IVIG lots for nAbs against SARS-CoV-2 and the longer-circulating HCoV-229E, to establish clarity about cross-neutralization of the pandemic virus by antibodies induced by earlier circulating seasonal coronaviruses. In addition, results from the ongoing monitoring of the plasma donor community for the development of SARS-COV-2 antibodies are presented."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T31","span":{"begin":18,"end":24},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T32","span":{"begin":25,"end":26},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T33","span":{"begin":192,"end":197},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T34","span":{"begin":323,"end":329},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"The current study tested a representative number of IVIG lots for nAbs against SARS-CoV-2 and the longer-circulating HCoV-229E, to establish clarity about cross-neutralization of the pandemic virus by antibodies induced by earlier circulating seasonal coronaviruses. In addition, results from the ongoing monitoring of the plasma donor community for the development of SARS-COV-2 antibodies are presented."}

{"project":"LitCovid-sentences","denotations":[{"id":"T21","span":{"begin":0,"end":266},"obj":"Sentence"},{"id":"T22","span":{"begin":267,"end":405},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The current study tested a representative number of IVIG lots for nAbs against SARS-CoV-2 and the longer-circulating HCoV-229E, to establish clarity about cross-neutralization of the pandemic virus by antibodies induced by earlier circulating seasonal coronaviruses. In addition, results from the ongoing monitoring of the plasma donor community for the development of SARS-COV-2 antibodies are presented."}

{"project":"LitCovid-PubTator","denotations":[{"id":"92","span":{"begin":79,"end":89},"obj":"Species"},{"id":"93","span":{"begin":117,"end":126},"obj":"Species"},{"id":"94","span":{"begin":252,"end":265},"obj":"Species"},{"id":"95","span":{"begin":369,"end":379},"obj":"Species"}],"attributes":[{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"Tax:2697049"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"Tax:11137"},{"id":"A94","pred":"tao:has_database_id","subj":"94","obj":"Tax:11118"},{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The current study tested a representative number of IVIG lots for nAbs against SARS-CoV-2 and the longer-circulating HCoV-229E, to establish clarity about cross-neutralization of the pandemic virus by antibodies induced by earlier circulating seasonal coronaviruses. In addition, results from the ongoing monitoring of the plasma donor community for the development of SARS-COV-2 antibodies are presented."}